暫無數據
Apotex Health Corp.(APTX)獲得加拿大皇家銀行資本市場買入評級。
Top News Today/Canada: Manufacturing Sector PMI Rises in July
Apotex Health Corp Price Target Raised to C$40.00/Share From C$36.00 by Raymond James
特朗普擬對進口仿製藥徵關稅:將如何影響藥價、藥企與藥品供應鏈
核心要點特朗普計劃設立兩年緩衝期,之後對進口仿製藥最高徵收 200% 關稅,以此推動藥品在美國本土生產。仿製藥企業利潤率微薄,相比原研藥企更難消化關稅成本,目前政策諸多關鍵細則尚未落地。分析師認爲,已在美國佈局產能的藥企更具抗壓優勢;最終影響取決於關稅落地執行方案。唐納德・特朗普總統提議對進口仿製藥徵收關稅,市場再度產生疑問:低價仿製藥廠商能否在最高 200% 關稅生效前,將產能轉移至美國本土。特
Press Release: Apotex Receives Investment Grade Issuer Rating From Morningstar DBRS and Announces Amended & Restated Credit Agreement
Apotex Receives Investment Grade Issuer Rating From Morningstar DBRS And Announces Amended & Restated Credit Agreement >APTX.T